J E Nelson1, P Handa2, B Aouizerat3,4, L Wilson5, L A Vemulakonda2, M M Yeh6, K V Kowdley1,2. 1. Benaroya Research Institute at Virginia Mason Medical Center, Seattle, WA, USA. 2. Liver Care Network and Organ Care Research Program, Swedish Medical Center, Seattle, WA, USA. 3. Department of Physiological Nursing, University of California at San Francisco, San Francisco, CA, USA. 4. Institute for Human Genetics, University of California at San Francisco, San Francisco, CA, USA. 5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 6. Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a complex, multifactorial disease affected by diet, lifestyle and genetics. Proinflammatory cytokines like IL-1β and IL-6 have been shown to be elevated in non-alcoholic steatohepatitis (NASH). AIM: To investigate the relationship between IL1B and IL6 gene polymorphisms and histological features of NAFLD in the NASH CRN cohort. METHODS: A total of 604 adult (≥18 years) non-Hispanic Caucasians with biopsy-proven NAFLD were genotyped for the following SNPs: IL1B, rs16944, rs1143634; IL6, rs1800795, rs10499563. Logistic regression was used to examine the relationship between genotype and a definitive diagnosis and advanced histological features of NASH after controlling for the following variables selected a priori: age, sex, diabetes, obesity and HOMA-IR level. RESULTS: The IL6 rs10499563 C allele was independently associated with the presence of definitive NASH, and increased ballooning and Mallory bodies. The IL1B rs1143634 TT genotype was associated with advanced fibrosis and increased Mallory bodies. The IL6 rs1800795 C allele was associated with not only increased risk for severe steatosis, >66% but also decreased risk for advanced fibrosis and lobular inflammation and Mallory body formation. CONCLUSIONS: These results suggest that common variants in the IL6 and IL1B genes may increase susceptibility for NASH and confer a higher risk of hepatic parenchymal damage including increased ballooning, increased Mallory bodies, and bridging fibrosis or cirrhosis. In contrast, the IL6 rs1800795 C allele may confer a higher risk for steatosis, but less parenchymal damage. Our findings support the development of therapeutics aimed at IL-1β and IL-6 suppression.
BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is a complex, multifactorial disease affected by diet, lifestyle and genetics. Proinflammatory cytokines like IL-1β and IL-6 have been shown to be elevated in non-alcoholic steatohepatitis (NASH). AIM: To investigate the relationship between IL1B and IL6 gene polymorphisms and histological features of NAFLD in the NASH CRN cohort. METHODS: A total of 604 adult (≥18 years) non-Hispanic Caucasians with biopsy-proven NAFLD were genotyped for the following SNPs: IL1B, rs16944, rs1143634; IL6, rs1800795, rs10499563. Logistic regression was used to examine the relationship between genotype and a definitive diagnosis and advanced histological features of NASH after controlling for the following variables selected a priori: age, sex, diabetes, obesity and HOMA-IR level. RESULTS: The IL6rs10499563 C allele was independently associated with the presence of definitive NASH, and increased ballooning and Mallory bodies. The IL1Brs1143634 TT genotype was associated with advanced fibrosis and increased Mallory bodies. The IL6rs1800795 C allele was associated with not only increased risk for severe steatosis, >66% but also decreased risk for advanced fibrosis and lobular inflammation and Mallory body formation. CONCLUSIONS: These results suggest that common variants in the IL6 and IL1B genes may increase susceptibility for NASH and confer a higher risk of hepatic parenchymal damage including increased ballooning, increased Mallory bodies, and bridging fibrosis or cirrhosis. In contrast, the IL6rs1800795 C allele may confer a higher risk for steatosis, but less parenchymal damage. Our findings support the development of therapeutics aimed at IL-1β and IL-6 suppression.
Authors: Elizabeth K Speliotes; Johannah L Butler; Cameron D Palmer; Benjamin F Voight; Joel N Hirschhorn Journal: Hepatology Date: 2010-09 Impact factor: 17.425
Authors: Andrew J P Smith; Francesco D'Aiuto; Jutta Palmen; Jackie A Cooper; Jane Samuel; Simon Thompson; Julie Sanders; Nikos Donos; Luigi Nibali; David Brull; Pat Woo; Steve E Humphries Journal: Clin Chem Date: 2008-03-20 Impact factor: 8.327
Authors: Louise Strandberg; Dan Mellström; Osten Ljunggren; Elin Grundberg; Magnus K Karlsson; Anna H Holmberg; Eric S Orwoll; Anna L Eriksson; Johan Svedberg; Magnus Bengtsson; Claes Ohlsson; John-Olov Jansson Journal: Obesity (Silver Spring) Date: 2008-01-17 Impact factor: 5.002
Authors: Vanessa D F de Mello; Marjukka Kolehmainen; Ursula Schwab; Ursula Mager; David E Laaksonen; Leena Pulkkinen; Leo Niskanen; Helena Gylling; Mustafa Atalay; Rainer Rauramaa; Matti Uusitupa Journal: Metabolism Date: 2008-02 Impact factor: 8.694
Authors: Norio Horiguchi; Lei Wang; Partha Mukhopadhyay; Ogyi Park; Won Il Jeong; Fouad Lafdil; Douglas Osei-Hyiaman; Akira Moh; Xin Yuan Fu; Pál Pacher; George Kunos; Bin Gao Journal: Gastroenterology Date: 2008-01-11 Impact factor: 22.682
Authors: Luisa Vonghia; Thea Magrone; An Verrijken; Peter Michielsen; Luc Van Gaal; Emilio Jirillo; Sven Francque Journal: PLoS One Date: 2015-11-24 Impact factor: 3.240
Authors: Rocío Gallego-Durán; Rocío Montero-Vallejo; Douglas Maya-Miles; Ana Lucena; Franz Martin; Javier Ampuero; Manuel Romero-Gómez Journal: Front Immunol Date: 2021-11-24 Impact factor: 7.561
Authors: Sarah E Kleinstein; Matthew Rein; Manal F Abdelmalek; Cynthia D Guy; David B Goldstein; Anna Mae Diehl; Cynthia A Moylan Journal: Hepatol Commun Date: 2018-09-05